Vaniqa in the treatment of facial hair

When a women experiences excessive growth of facial hair it means that she has a condition called hirsutism.

Usually hirsutism is a hereditary condition common for the entire family. However, in some cases hormonal disorders (like excessive production of male sexual hormones - testosterone) or increased sensitivity of the hair follicles to testosterone may result in excessive facial hair growth in women. The treatment of facial hair growth is based on determination the main cause of the disease. There are some symptoms which can help to determined whether facial hair growth is related to hormonal disorders. These symptoms include:

• Irregular menstrual cycle
• Owerweight
• Decreased size of breast
• Baldness

A women can develop a sudden facial growth which can be a sign of androgen-producing tumor. Androgen-producing tumor are found in adrenal glands or ovaries. In most cases women with hirsutism develop the symptoms at early twenties and with ages the symptoms get worse.

Hormonal dis-balance can be also a result of hormonal contraceptives application, period of menopause, infectious diseases of the pituitary or adrenal glands.

Vaniqa is used to reduce unwanted facial hair in women

The treatment of facial hair growth includes the application of certain medication which normalize hormonal disbalance. In case when the exact cause of hirsutism is not found, topical medications can be used. Vaniqa is one of the most prescribed drug in the treatment of facial hair. Vaniqa interferes with a chemical in the hair follicles of the skin. This results in slower hair growth where Vaniqa is applied.

Vaniqa is used to reduce unwanted facial hair in women. It does not permanently remove hair or "cure" unwanted facial hair. However it will help you manage your condition and improve your appearance.

Vaniqa may also be used for purposes other than those listed in this medication guide. Do not use Vaniqa if you have had an allergic reaction to it in the past. Vaniqa is in the FDA pregnancy category C. This means that it is not known whether eflornithine will harm an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant. It is also not known whether eflornithine passes into breast milk. Do not use this medicine without first talking to your doctor if you are breast-feeding a baby. Vaniqa has not been approved for use by children younger than 12 years of age. If you miss a dose of Vaniqa, skip the dose you missed and apply your next regularly scheduled dose as directed. Do not apply a double dose of this medication or try to "make up" a missed dose. An overdose is not likely to occur. If the cream has been ingested, or if you suspect an overdose has occurred, contact your doctor, hospital emergency room, or poison control center for advice. Avoid getting this medication in your eyes, nose, or mouth. If this occurs, wash the area with water. If Vaniqa gets in your eyes, rinse thoroughly with water and contact your doctor.